UCL Cancer Institute


Extensive CT and MR Imaging facilities are available at UCLH. Additionally, there are two PET scanners, a dedicated research SPECT/CT scanner and a PET/MRI will be installed in the new Cancer Centre in 2012. A dedicated Phase I radiologist provides a reporting service, supporting the Phase I multidisciplinary team.


The newly installed research SPECT/CT will support trials of radio-targeted therapy and molecular imaging. Illustrated is an example from a recently completed trial using 131I-L19-SIP which is a radiolabelled small immunopeptide that targets the extra-domain B of fibronectin expressed in tumour vasculature. The immunoconjugate is selectively taken up in the neck tumour with a high tumour to background ratio at 48 hours.